Symbiomix today announced it has hired David L. Stern, MBA, a seasoned biopharmaceutical executive with over 20 years of experience leading the commercialization of treatments in women’s health and fertility, as Chief Executive Officer of the company.
Mr. Stern joins Symbiomix on the heels of the company’s recent submission of a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for its drug candidate Solosec™, an innovative antibiotic designed to treat BV. The company hired Taunia Markvicka, PharmD, MBA, as Chief Commercial Officer in 2016 and has been rapidly preparing for the commercialization of Solosec™.